TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma. Gallina FT, Marinelli D, Taje R, Visca P, et al. Eur J Cancer 2025;227:115622.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gallina FT, Marinelli D, Taje R, Visca P, et al. TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma. Eur J Cancer 2025;227:115622.
PMID: 40680467